down arrow

Hunan Hansen Pharmaceutical Co. Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000PK2
CNY
7.03
0.1 (1.44%)

Dec 04

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Hunan Hansen Pharmaceutical Co. Ltd.
Why is Hunan Hansen Pharmaceutical Co. Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 5.81% and Operating profit at 9.81% over the last 5 years
  • NET PROFIT(Q) At CNY 10.83 MM has Fallen at -80.16%
  • DEBTORS TURNOVER RATIO(HY) Lowest at 2.26%
  • EPS(Q) Lowest at CNY 0.02
2
Underperformed the market in the last 1 year
  • The stock has generated a return of 3.41% in the last 1 year, much lower than market (China Shanghai Composite) returns of 15.18%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hunan Hansen Pharmaceutical Co. Ltd. for you?

Medium Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Hunan Hansen Pharmaceutical Co. Ltd.
6.52%
0.83
27.60%
China Shanghai Composite
14.77%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
5.81%
EBIT Growth (5y)
9.81%
EBIT to Interest (avg)
45.43
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.44
Tax Ratio
13.46%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.69%
ROE (avg)
9.10%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
1.38
EV to EBIT
10.28
EV to EBITDA
8.88
EV to Capital Employed
1.45
EV to Sales
2.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
14.12%
ROE (Latest)
8.27%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 176.62 MM

RAW MATERIAL COST(Y)

Fallen by -5.43% (YoY

CASH AND EQV(HY)

Highest at CNY 790.09 MM

DEBT-EQUITY RATIO (HY)

Lowest at -15.27 %

-12What is not working for the Company
NET PROFIT(Q)

At CNY 10.83 MM has Fallen at -80.16%

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.26%

EPS(Q)

Lowest at CNY 0.02

Here's what is working for Hunan Hansen Pharmaceutical Co. Ltd.
Operating Cash Flow
Highest at CNY 176.62 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Cash and Eqv
Highest at CNY 790.09 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -15.27 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -5.43% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hunan Hansen Pharmaceutical Co. Ltd.
Net Profit
At CNY 10.83 MM has Fallen at -80.16%
over average net sales of the previous four periods of CNY 54.61 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Profit
Lowest at CNY 10.83 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS
Lowest at CNY 0.02
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Debtors Turnover Ratio
Lowest at 2.26%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."